Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

详细信息    查看全文

• 作者：Mikkel Christensen (1)
  Filip K. Knop (1)
  
• 关键词：Albiglutide ; Albugon ; CJC ; 1131 ; CJC ; 1134 ; PC ; Exenatide ; Exenatide once weekly ; Glucagon ; like peptide ; 1 ; GLP ; 1 agonist ; Incretin mimetics ; Long ; acting release ; Taspoglutide ; Type 2 diabetes
• 刊名：Current Diabetes Reports
• 出版年：2010
• 出版时间：April 2010
• 年：2010
• 卷：10
• 期：2
• 页码：124-132
• 全文大小：193KB
• 参考文献：1. 鈥?Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409鈥?439. / This is an excellent review of the physiologic effects of GLP-1, which provide the basis for understanding the therapeutic use of GLP-1鈥揵ased therapy.
  2. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952鈥?57. CrossRef
  3. Mentlein R: Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9鈥?4. CrossRef
  4. Deacon CF, Nauck MA, Toft-Nielsen M, et al.: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126鈥?131. CrossRef
  5. Fehmann HC, G枚ke R, G枚ke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995, 16:390鈥?10.
  6. Egan JM, Bulotta A, Hui H, Perfetti R: GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003, 19:115鈥?23. CrossRef
  7. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999, 48:2358鈥?366. CrossRef
  8. Buteau J, El-Assaad W, Rhodes CJ, et al.: Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47:806鈥?15. CrossRef
  9. Larsson H, Holst JJ, Ahr茅n B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997, 160:413鈥?22. CrossRef
  10. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515鈥?20. CrossRef
  11. Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962鈥?65. CrossRef
  12. Nikolaidis LA, Elahi D, Hentosz T, et al.: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955鈥?61. CrossRef
  13. Meier JJ, Gethmann A, G枚tze O, et al.: Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452鈥?58. CrossRef
  14. Nystr枚m T, Gutniak MK, Zhang Q, et al.: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209鈥揈1215. CrossRef
  15. Carraro-Lacroix LR, Malnic G, Girardi ACC: Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 2009, 297:F1647鈥揊1655. CrossRef
  16. Li Y, Perry T, Kindy MS, et al.: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009, 106:1285鈥?290. CrossRef
  17. During MJ, Cao L, Zuzga DS, et al.: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173鈥?179. CrossRef
  18. Eng J, Kleinman WA, Singh L, et al.: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402鈥?405.
  19. Thorens B, Porret A, B眉hler L, et al.: Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678鈥?682. CrossRef
  20. European Medicines Agency: EPARs for authorised medicinal products for human use. Byetta: Scientific Discussion (6). Available at http://www.ema.europa.eu/humandocs/Humans/EPAR/byetta/byetta.htm. Accessed February 2010.
  21. Simonsen L, Holst JJ, Deacon CF: Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006, 49:706鈥?12. CrossRef
  22. Bosi E, Lucotti P, Setola E, et al.: Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes Res Clin Pract 2008, 82(Suppl 2):S102鈥揝107. CrossRef
  23. Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559鈥?69.
  24. Nauck MA, Duran S, Kim D, et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259鈥?67. CrossRef
  25. Madsbad S, Krarup T, Deacon CF, Holst JJ: Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008, 11:491鈥?99. CrossRef
  26. Klonoff DC, Buse JB, Nielsen LL, et al.: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3聽years. Curr Med Res Opin 2008, 24:275鈥?86.
  27. Okerson T, Yan P, Stonehouse A, Brodows R: Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes. Am J Hypertens 2009 Dec 17 [Epub ahead of print].
  28. Elbr酶nd B, Jakobsen G, Larsen S, et al.: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25:1398鈥?404. CrossRef
  29. Garber A, Henry R, Ratner R, et al.: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473鈥?81. CrossRef
  30. Nauck M, Frid A, Hermansen K, et al.: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84鈥?0. CrossRef
  31. Marre M, Shaw J, Br盲ndle M, et al.: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26聽weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268鈥?78. CrossRef
  32. Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224鈥?230. CrossRef
  33. Buse JB, Rosenstock J, Sesti G, et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39鈥?7. CrossRef
  34. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194鈥?06. CrossRef
  35. European Medicines Agency: EPARs for authorised medicinal products for human use. Victoza: Public assessment report (6). Available from: http://www.ema.europa.eu/humandocs/Humans/EPAR/victoza/victoza.htm. Accessed February 2010.
  36. Blonde L, Russell-Jones D: The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009, 11(Suppl 3):26鈥?4. CrossRef
  37. Russell-Jones D, Vaag A, Schmitz O, et al.: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046鈥?055. CrossRef
  38. Thibaudeau K, Robitaille M, Wen S, Paradis V: / CJC-1134-PC: An Exendin-4 Conjugate with Extended Pharmacodynamic Profiles in Rodents [abstract 434-P]. Presented at the 66th Scientific Sessions of the American Diabetes Association. Washington, D.C.; June 9鈥?3, 2006.
  39. Wang M, Kipnes M, Matheson S, Wen S: / Safety and Pharmacodynamics of CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study [abstract 0498-P]. Presented at the 67th Scientific Sessions of the American Diabetes Association. Chicago, IL; June 21鈥?5, 2007.
  40. Wang M, Matheson S, Picard J, Pezzullo J: / PC-DAC鈩? Exendin-4 (CJC-1134-PC) Significantly Reduces HbA1c and Body Weight as an Adjunct Therapy to Metformin: Two Randomized, Double-Blind, Placebo-Controlled, 12 Week, Phase II Studies in Patients with Type 2 Diabetes Mellitus [abstract 553-P]. Presented at the 69th Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 5鈥?, 2009.
  41. L茅ger R, Thibaudeau K, Robitaille M, et al. : Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7鈥?6) analog. Bioorg Med Chem Lett 2004, 14:4395鈥?398. CrossRef
  42. Kim J, Baggio LL, Bridon DP, et al. : Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52:751鈥?59. CrossRef
  43. Baggio LL, Huang Q, Cao X, Drucker DJ: An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008, 134:1137鈥?147. CrossRef
  44. Baggio LL, Huang Q, Brown TJ, Drucker DJ: A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492鈥?500. CrossRef
  45. Bush MA, Matthews JE, De Boever EH, et al.: Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009, 11:498鈥?05. CrossRef
  46. Rosenstock J, Reusch J, Bush M, et al.: Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880鈥?886. CrossRef
  47. Matthews JE, Stewart MW, De Boever EH, et al.: Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:4810鈥?817. CrossRef
  48. Seino Y, Nakajima H, Miyahara H, et al.: Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009, 25:3049鈥?057. CrossRef
  49. Woon C, Taylor J, Dong J, Shen Y: / BIM 51077, A Stable Glucagon-Like Peptide-1 (GLP-1) Analogue With Preserved Gluco-Incretin Property in Vitro [abstract P1-359]. Presented at the Program of the Endocrine Society's 83聽rd Annual Meeting. Denver, CO; June 19鈥?3, 2001.
  50. Wargent E, Nolan A, Shen Y, Dong J: Insulin secretagogue activity in vitro and in perfused pancreas of dipeptidase IV resistant GLP-1 analogs. Diabetologia 2000, 44(Suppl 1):Abstract 532.
  51. Culler M, Carlile L, Sullivan T, Taylor J: / BIM-51077, A Novel Glucagon-Like Peptide-1 (GLP-1) Analog With Enhanced in Vivo Efficacy [abstract P1-360]. Presented at the Program of the Endocrine Society's 83聽rd Annual Meeting. Denver, CO; June 19鈥?3, 2001.
  52. Kapitza C, Heise T, Birman P, et al.: Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with type 2 diabetes. Diabet Med 2009, 26:1156鈥?164. CrossRef
  53. Nauck MA, Ratner RE, Kapitza C, et al.: Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009, 32:1237鈥?243. CrossRef
  54. Ratner R, Nauck M, Asnaghi V, Berria R: Safety and tolerability of high doses of the long acting, human GLP-1 analogue R1583 in diabetic subjects treated with metformin: a double-blind, placebo-controlled phase 2 study. Diabetes 2008, 57(Suppl 1):Abstract 10-O.
  55. Tracy MA, Ward KL, Firouzabadian L, et al.: Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999, 20:1057鈥?062. CrossRef
  56. Verspohl EJ: Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009, 124:113鈥?38. CrossRef
  57. Kim D, MacConell L, Zhuang D, et al.: Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487鈥?493. CrossRef
  58. 鈥⑩€?Drucker DJ, Buse JB, Taylor K, et al.: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240鈥?250. / This is presently the only published head-to-head comparison of short-acting versus long-acting GLP-1 analogues.
  59. Iwamoto K, Nasu R, Yamamura A, et al.: Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009, 56:951鈥?62. CrossRef
  60. Gedulin BR, Smith P, Prickett KS, et al.: Dose-response for glycaemic and metabolic changes 28聽days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005, 48:1380鈥?385. CrossRef
  61. Mazze R, Strock E, Morgan B, et al.: Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. Endocr Pract 2009, 15:326鈥?34. CrossRef
  62. Best JH, Boye KS, Rubin RR, et al.: Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009, 26):722鈥?28.
  
• 作者单位：Mikkel Christensen (1)
  Filip K. Knop (1)
  
  1. Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900, Hellerup, Denmark
  

文摘

Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.